Adenanthin

Cell Death Dis. 2014 Sep 4;5:e1400.

Adenanthin targets peroxiredoxin I/II to kill hepatocellular carcinoma cells.[Pubmed: 25188510]

Adenanthin, has recently been reported to induce leukemic cell differentiation by targeting peroxiredoxins (Prx) I and II. On the other hand, increasing lines of evidence propose that these Prx proteins would become potential targets to screen drugs for the prevention and treatment of solid tumors. Therefore, it is of significance to explore the potential activities of Adenanthin on solid tumor cells.
METHODS AND RESULTS:
Here, we demonstrate that Prx I protein is essential for the survival of hepatocellular carcinoma (HCC) cells, and Adenanthin can kill these malignant liver cells in vitro and xenografts. We also show that the cell death-inducing activity of Adenanthin on HCC cells is mediated by the increased reactive oxygen species (ROS) levels. Furthermore, the silencing of Prx I or Prx II significantly enhances the cytotoxic activity of Adenanthin on HCC, whereas the ectopic expression of Prx I and Prx II but not their mutants of Adenanthin-bound cysteines can rescue Adenanthin-induced cytotoxicity in Prxs-silenced HCC cells.
CONCLUSIONS:
Taken together, our results propose that Adenanthin targets Prx I/II to kill HCC cells and its therapeutic significance warrants to be further explored in HCC patients.

Biochem Pharmacol. 2014 May 15;89(2):210-6.

Adenanthin targets proteins involved in the regulation of disulphide bonds.[Pubmed: 24630929]

Adenanthin has been recently shown to inhibit the enzymatic activities of peroxiredoxins (Prdx) I and II through its functional α,β-unsaturated ketone group serving as a Michael acceptor. A similar group is found in SK053, a compound recently developed by our group to target the thioredoxin-thioredoxin reductase (Trx-TrxR) system.
METHODS AND RESULTS:
This work provides evidence that next to Prdx I and II Adenanthin targets additional proteins including thioredoxin-thioredoxin reductase system as well as protein disulfide isomerase (PDI) that contain a characteristic structural motif, referred to as a thioredoxin fold. Adenanthin inhibits the activity of Trx-TR system and PDI in vitro in the insulin reduction assay and decreases the activity of Trx in cultured cells. Moreover, we identified Trx-1 as an Adenanthin binding protein in cells incubated with biotinylated Adenanthin as an affinity probe.
CONCLUSIONS:
The results of our studies indicate that Adenanthin is a mechanism-selective, rather than an enzyme-specific inhibitor of enzymes containing readily accessible, nucleophilic cysteines. This observation might be of importance in considering potential therapeutic applications of Adenanthin to include a range of diseases, where aberrant activity of Prdx, Trx-TrxR and PDI is involved in their pathogenesis.

Nat Chem Biol. 2012 Apr 8;8(5):486-93.

Adenanthin targets peroxiredoxin I and II to induce differentiation of leukemic cells.[Pubmed: 22484541]

Peroxiredoxins (Prxs) are potential therapeutic targets for major diseases such as cancers. However, isotype-specific inhibitors remain to be developed.
METHODS AND RESULTS:
We report that Adenanthin, a diterpenoid isolated from the leaves of Rabdosia adenantha, induces differentiation of acute promyelocytic leukemia (APL) cells. We show that Adenanthin directly targets the conserved resolving cysteines of Prx I and Prx II and inhibits their peroxidase activities. Consequently, cellular H(2)O(2) is elevated, leading to the activation of extracellular signal-regulated kinases and increased transcription of CCAAT/enhancer-binding protein β, which contributes to Adenanthin-induced differentiation. Adenanthin induces APL-like cell differentiation, represses tumor growth in vivo and prolongs the survival of mouse APL models that are sensitive and resistant to retinoic acid.
CONCLUSIONS:
Thus, Adenanthin can serve as what is to our knowledge the first lead natural compound for the development of Prx I- and Prx II-targeted therapeutic agents, which may represent a promising approach to inducing differentiation of APL cells.

J Immunol. 2013 Sep 1;191(5):2115-25.

Preventive and therapeutic effects of adenanthin on experimental autoimmune encephalomyelitis by inhibiting NF-κB signaling.[Pubmed: 23964105]

Adenanthin, a diterpenoid isolated from the leaves of Isodon adenanthus, has been reported to possess antileukemic activity through targeting peroxiredoxin I/II. However, its other potential activities remain to be explored.
METHODS AND RESULTS:
Using myelin oligodendrocyte glycoprotein (MOG)35-55-induced experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, we report in this study that Adenanthin exerts efficaciously preventive and therapeutic effects on EAE accompanied by significant restriction of infiltration of inflammatory cells and demyelination in CNS. Adenanthin-presented immunomodulatory effects on EAE are correlated with suppressed proliferation of MOG35-55-reactive T cells, decreased Th1 and Th17 cells, increased regulatory T cell populations, decreased production of serum proinflammatory cytokines, and reduced stimulatory capacity of APCs, which might be mediated by its inhibitory action on NF-κB signaling pathway.
CONCLUSIONS:
Our results propose that, as a novel NF-κB inhibitor, Adenanthin has potent immunomodulatory activity for the treatment of multiple sclerosis and possibly other autoimmune disorders.